Objective: This study aims to describe the establishment of the Mexican Parkinson’s Research Network (MEX-PD), a consortium dedicated to investigating the clinical, genetic, environmental, and neurophysiological underpinnings of phenotypic diversity in Mexican Parkinson’s disease (PD) patients and to present preliminary clinical and genetic outcomes. Methods: PD patients and control participants were recruited from medical centers across Mexico. The initial recruitment phase involved comprehensive neurological evaluations, cognitive assessments, and DNA collection. We conducted classical statistical analyses on clinical variables. Secondly, following genotyping with NeuroBooster array, quality control and imputation, preliminary analysis of ancestry composition, allele frequency calculation and association analysis was carried out for 294 samples. Results: The cohort consisted of 530 control participants and 470 PD patients, with a mean age of diagnosis of 59.9 ± 11.52 years. Among the PD patients, 21.2% were identified as having early-onset PD (<50 years old). Ancestry composition analysis revealed that the main components were European (49.8% in cases and 42.4% in controls) and Native American (46.1% in cases and 54.3% in controls). Variants in genes such as NOTCH , LRRK2 , MTHFR and KPNA1 emerged as relevant to be prioritized in future studies. Conclusions: The MEX-PD consortium will contribute to the understanding of PD within the Mexican population. The data collected will enable a deeper comprehension of the specific contributions of genetic and environmental factors to these outcomes. Significance: This research advocates for the development of personalized treatments and aims to improve the quality of life for Mexican PD patients.
4 August 2026 in Aging Clinical and Experimental Research
Background Parkinson’s disease (PD) may present with early-onset (EOPD) or late-onset (LOPD). Lower cognitive performance has been reported more frequently in LOPD, although findings remain inconsistent, partly due to limited control of confounders such as age at assessment, education, and disease severity. Aims To evaluate associations of age at assessment, age at onset, education, clinical severity, and emotional factors with cognitive performance in PD, and to compare performance between EOPD, LOPD, and controls in Mexico. Methods We analyzed 249 patients with PD and 102 healthy controls from the Mex-PD cohort. Cognition was assessed using the Montreal Cognitive Assessment (MoCA). Multiple linear regression models identified variables associated with cognitive performance. Given collinearity among age-related variables, moderation analyses examined interactions between age at assessment, age at onset, group, and disease severity. Nearest-neighbor matching was used for group comparisons. Results Age at assessment was most strongly associated with lower cognitive performance, followed by education and disease severity. Age at onset was not independently associated with cognition. Cognitive differences between EOPD and LOPD disappeared after controlling for age at assessment. Disease severity was significantly associated with lower cognitive performance from 59 years onward. In matched samples, both PD groups showed lower global cognition than controls, with delayed recall most affected. Conclusions In this cross-sectional study, lower cognitive performance in PD was more strongly associated with age at assessment and its interaction with disease severity than with age at onset. Education and cognitive reserve were positively associated with cognitive performance, consistent with their protective role.